



Lateral Pharma Pty Ltd
ABN: 40 605 241 665

Level 14/114 William Street
Melbourne, VIC, 3000

www.lateral-pharma.com
info@lateral-pharma.com

11 August 2021

Lateral Accepted into the US National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative Preclinical Screening Platform for Pain (PSPP) Program

We are pleased to announce that Lateral Pharma has been accepted into the NIH HEAL InitiativeSM PSPP program.

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: <https://heal.nih.gov>.

The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical models. The PSPP program accepts small molecules, biologics, devices, or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: <https://heal.nih.gov/research/preclinical-translational/screening-platform>

Further Information

David Kenley OAM, B.Ec, MEI

Chief Executive Officer

E: dk@lateral-pharma.com

M: 0400 151 490